Top-News
Biotechnologie Norwegen

ULTIMOVACS ASA Aktie

Aktie
WKN:  A2PKSD ISIN:  NO0010851603
0,1932 €
+0,0038 €
+2,01%
06.12.24
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-

ULTIMOVACS ASA News

18.10.22 - GlobeNewswire
Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
21.09.22 - GlobeNewswire
Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR)
New clinical data from phase I trial UV1-103, combining UV1 with pembrolizumab in advanced melanoma will be presented Oslo, September 21  2022 : Ultimovacs ASA ("Ultimovac...
12.09.22 - GlobeNewswire
Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine
Comprehensive characterization of phase I UV1-checkpoint inhibitor combination trial Clinical responses seen in patients with favored and less favored baseline characteristics T ...
09.09.22 - GlobeNewswire
Ultimovacs ASA: New share capital registered
Oslo, 9 September 2022, Ultimovacs ASA (the "Company") refers to the announcement published on 5 September 2022 regarding the issuance of new shares in connection with ...
05.09.22 - GlobeNewswire
Ultimovacs ASA: Mandatory notification of trade by primary insider
Oslo, 05 September 2022, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an average price of ...
05.09.22 - GlobeNewswire
Ultimovacs ASA: Share capital increase related to exercise of options
Oslo, 05 September 2022, the Board of Directors of Ultimovacs ASA (the "Company") has resolved to increase the Company's share capital by NOK 4,400 through the issuance of ...
22.08.22 - GlobeNewswire
Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent
Will cover methods for eliciting T cell immune response Protects US sales and marketing of UV1 Oslo, August 22, 2022 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage ...
19.08.22 - GlobeNewswire
Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update
Oslo, August 19, 2022 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second quarter 2022 results ...
18.08.22 - GlobeNewswire
Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review
The TENDU interim safety results from nine patients show no safety concerns Trial extended to enroll up to three additional patients at the highest dose level TENDU designed to ...
12.08.22 - GlobeNewswire
Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation
Oslo , 12 August 202 2 : Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its second ...
30.06.22 - GlobeNewswire
Ultimovacs ASA: Mandatory notification of trade by primary insider
Oslo, 30 June 2022, a closely related party of Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 2,000 shares in the company at an ...
30.06.22 - GlobeNewswire
Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma
Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 months Study provides randomized data on impact of UV1 on standard-​of-care immunotherapy ...
20.06.22 - GlobeNewswire
Ultimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial
30 patients treated with UV1/pembrolizumab 24-month survival rate of 73% Promising survival data follows encouraging clinical response rates and good safety O slo, 20 June ...
25.05.22 - GlobeNewswire
Ultimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy
Data from three trials of UV1 show dynamic T cell responses, lasting up to 7.5 years UV1-specific immune responses associated with longer clinical survival Synergy between UV1 ...
12.05.22 - GlobeNewswire
Ultimovacs ASA: First quarter 2022 result presentation
Oslo, 12 May 202 2 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its first quarter 2022 results today.
10.05.22 - GlobeNewswire
Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting
UV1 immune monitoring data from three Phase I/IIa clinical trials show dynamic T cell responses lasting up to 7.5 years Measurable UV1-specific immune response in 91% of ...
05.05.22 - GlobeNewswire
Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation
Ultimovacs ASA: Invitation to first quarter 202 2 results webcast presentation
22.04.22 - GlobeNewswire
Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations
Extends protection for UV1 vaccine-​checkpoint inhibitor combinations until at least 2037 Covers UV1 with CTLA-4, PD-1 or PD-L1 checkpoint inhibitors Oslo, 22 April 202 2 ...
21.04.22 - GlobeNewswire
Ultimovacs ASA - Share Option Program
Oslo, 2 1 April 202 2 : On the basis of the approval by the General Meeting on 21 April 202 2 to authorize the Board of Directors of Ultimovacs ASA (the ‘Company’, OSE ticker “ULTI”) to ...
21.04.22 - GlobeNewswire
Ultimovacs ASA – Annual General Meeting held on 21 April 2022
Oslo, 21 April 202 2 : Ultimovacs ASA held its annual general meeting today 21 April 2022. All the matters on the agenda were approved.

Newssuche

Videos

newspaper
05.12.24 -2,79%
Technical Trading: Gold Long bis...
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 7 Laufzeit: OpenEnd Einstieg: Market ... Mehr »